February 2, 2018 09:45 AM EST
Financing
China

Bil­lion-dol­lar biosim mak­er mulls $500M Hong Kong IPO

Brittany Meiling

A Chi­nese biosim­i­lar mak­er val­ued at $1.5 bil­lion might be the first to list its stock on Hong Kong’s ex­change un­der new rules al­low­ing star­tups …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Where the mon­ey is: The top 100 ven­ture in­vestors in biotech

J&J seeks to stop Sam­sung Bioepis from li­cens­ing Ste­lara biosim­i­lar

Lil­ly pays $10M up­front for Organo­vo’s FXR ag­o­nist pro­gram

Com­pounders sue FDA over re­moval of semaglu­tide from of­fi­cial short­age list

Can­del's vi­ral ther­a­py shows promis­ing sur­vival in small pan­cre­at­ic can­cer study

sponsored

How AI can ad­dress on­go­ing chal­lenges in the life sci­ences in­dus­try

A service from the Financial Times